Detalles de la búsqueda
1.
Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma.
Cancer Immunol Immunother
; 73(8): 160, 2024 Jun 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38850335
2.
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab.
J Transl Med
; 21(1): 140, 2023 02 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-36823670
3.
Concomitant medication of cetirizine in advanced melanoma could enhance anti-PD-1 efficacy by promoting M1 macrophages polarization.
J Transl Med
; 20(1): 436, 2022 09 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36180872
4.
Management of cutaneous melanoma: radiologists challenging and risk assessment.
Radiol Med
; 127(8): 899-911, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35834109
5.
Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma.
Expert Opin Emerg Drugs
; 26(2): 79-92, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33686894
6.
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice.
J Transl Med
; 17(1): 376, 2019 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31730009
7.
The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.
Curr Oncol Rep
; 21(9): 76, 2019 07 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-31359162
8.
Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis.
J Transl Med
; 15(1): 82, 2017 04 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-28441954
9.
Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.
Br J Cancer
; 115(11): 1280-1284, 2016 Nov 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-27711085
10.
Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial.
Cancer Immunol Immunother
; 65(11): 1395-1400, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27604993
11.
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.
Cancer Lett
; 596: 217001, 2024 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38838764
12.
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.
Eur J Cancer
; 199: 113563, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38278007
13.
Immunotherapy Assessment: A New Paradigm for Radiologists.
Diagnostics (Basel)
; 13(2)2023 Jan 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-36673112
14.
BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes.
Eur J Cancer
; 179: 87-97, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36509002
15.
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma.
Eur J Cancer
; 194: 113354, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37827067
16.
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival.
Cancers (Basel)
; 15(20)2023 Oct 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37894419
17.
Dermatologic adverse events associated with targeted therapies for melanoma.
Expert Opin Drug Saf
; 21(3): 385-395, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34595993
18.
Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors.
Front Immunol
; 13: 811131, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35173725
19.
PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab.
Front Immunol
; 13: 962669, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36016960
20.
Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma.
Theranostics
; 12(17): 7420-7430, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36438490